6 research outputs found
Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report
Abstracts Background Giant Cell Arteritis (GCA) is a large vessel vasculitis that most commonly presents with headache, scalp tenderness, jaw claudication, and vision changes. Various other, less common, manifestations have been reported in the literature such as scalp and tongue necrosis. Though most patients respond to corticosteroids, some cases of GCA are refractory to the high doses of corticosteroids. Case presentation We present a 73-year-old female with GCA refractory to corticosteroids presenting with tongue necrosis. This patient significantly improved with a dose of tocilizumab, an IL-6 inhibitor. Conclusion To the best of our knowledge, this is the first case report of a patient with refractory GCA presenting with tongue necrosis that had rapid improvement with tocilizumab. Prompt diagnosis and treatment can prevent severe outcomes such as tongue amputation in GCA patients with tongue necrosis, and tocilizumab may be effective for corticosteroid-refractory cases
Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository
Abstract
Background
Antiphospholipid syndrome (APS) is characterized by episodes of thrombosis, obstetric morbidity or both, associated with persistently positive antiphospholipid antibodies (aPL). Studying the profile of a rare disease in an admixed population is important as it can provide new insights for understanding an autoimmune disease. In this sense of miscegenation, Brazil is characterized by one of the most heterogeneous populations in the world, which is the result of five centuries of interethnic crosses of people from three continents. The objective of this study was to compare the clinical and laboratory characteristics of Brazilian vs. non-Brazilian primary antiphospholipid syndrome (PAPS) patients.
Methods
We classified PAPS patients into 2 groups: Brazilian PAPS patients (BPAPS) and PAPS patients from other countries (non-BPAPS). They were compared regarding demographic characteristics, criteria and non-criteria APS manifestations, antiphospholipid antibody (aPL) profile, and the adjusted Global Antiphospholipid Syndrome Score (aGAPSS).
Results
We included 415 PAPS patients (88 [21%] BPAPS and 327 [79%] non-BPAPS). Brazilian patients were significantly younger, more frequently female, sedentary, obese, non-white, and had a higher frequency of livedo (25% vs. 10%, pâ<â0.001), cognitive dysfunction (21% vs. 8%, pâ=â0.001) and seizures (16% vs. 7%, pâ=â0.007), and a lower frequency of thrombocytopenia (9% vs. 18%, pâ=â0.037). Additionally, they were more frequently positive for lupus anticoagulant (87.5% vs. 74.6%, pâ=â0.01), and less frequently positive to anticardiolipin (46.6% vs. 73.7%, pâ<â0.001) and anti-Ă2-glycoprotein-I (13.6% vs. 62.7%, pâ<â0.001) antibodies. Triple aPL positivity was also less frequent (8% vs. 41.6%, pâ<â0.001) in Brazilian patients. Median aGAPSS was lower in the Brazilian group (8 vs. 10, pâ<â0.0001). In the multivariate analysis, BPAPS patients still presented more frequently with livedo, cognitive dysfunction and sedentary lifestyle, and less frequently with thrombocytopenia and triple positivity to aPL. They were also less often white.
Conclusions
Our study suggests a specific profile of PAPS in Brazil with higher frequency of selected non-criteria manifestations and lupus anticoagulant positivity. Lupus anticoagulant (not triple positivity) was the major aPL predictor of a classification criteria event.http://deepblue.lib.umich.edu/bitstream/2027.42/174072/1/42358_2021_Article_222.pd
Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository
Background Antiphospholipid syndrome (APS) is characterized by episodes
of thrombosis, obstetric morbidity or both, associated with persistently
positive antiphospholipid antibodies (aPL). Studying the profile of a
rare disease in an admixed population is important as it can provide new
insights for understanding an autoimmune disease. In this sense of
miscegenation, Brazil is characterized by one of the most heterogeneous
populations in the world, which is the result of five centuries of
interethnic crosses of people from three continents. The objective of
this study was to compare the clinical and laboratory characteristics of
Brazilian vs. non-Brazilian primary antiphospholipid syndrome (PAPS)
patients. Methods We classified PAPS patients into 2 groups: Brazilian
PAPS patients (BPAPS) and PAPS patients from other countries
(non-BPAPS). They were compared regarding demographic characteristics,
criteria and non-criteria APS manifestations, antiphospholipid antibody
(aPL) profile, and the adjusted Global Antiphospholipid Syndrome Score
(aGAPSS). Results We included 415 PAPS patients (88 [21%] BPAPS and
327 [79%] non-BPAPS). Brazilian patients were significantly younger,
more frequently female, sedentary, obese, non-white, and had a higher
frequency of livedo (25% vs. 10%, p < 0.001), cognitive dysfunction
(21% vs. 8%, p = 0.001) and seizures (16% vs. 7%, p = 0.007), and a
lower frequency of thrombocytopenia (9% vs. 18%, p = 0.037).
Additionally, they were more frequently positive for lupus anticoagulant
(87.5% vs. 74.6%, p = 0.01), and less frequently positive to
anticardiolipin (46.6% vs. 73.7%, p < 0.001) and
anti-ss2-glycoprotein-I (13.6% vs. 62.7%, p < 0.001) antibodies.
Triple aPL positivity was also less frequent (8% vs. 41.6%, p < 0.001)
in Brazilian patients. Median aGAPSS was lower in the Brazilian group (8
vs. 10, p < 0.0001). In the multivariate analysis, BPAPS patients still
presented more frequently with livedo, cognitive dysfunction and
sedentary lifestyle, and less frequently with thrombocytopenia and
triple positivity to aPL. They were also less often white. Conclusions
Our study suggests a specific profile of PAPS in Brazil with higher
frequency of selected non-criteria manifestations and lupus
anticoagulant positivity. Lupus anticoagulant (not triple positivity)
was the major aPL predictor of a classification criteria event
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (âRegistryâ)
Objectives To describe the outcomes of pregnancies in antiphospholipid antibody (aPL)-positive patients since the inception of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Registry.Methods We identified persistently aPL-positive patients recorded as âpregnantâ during prospective follow-up, and defined âaPL-related outcomeâ as a composite of: (1) Preterm live delivery (PTLD) at or before 37th week due to pre-eclampsia (PEC), eclampsia, small-for-gestational age (SGA) and/or placental insufficiency (PI); or (2) Otherwise unexplained fetal death after the 10th week of gestation. The primary objective was to describe the characteristics of patients with and without aPL-related composite outcomes based on their first observed pregnancies following registry recruitment.Results Of the 55 first pregnancies observed after registry recruitment among nulliparous and multiparous participants, 15 (27%) resulted in early pregnancy loss <10 weeks gestation. Of the remaining 40 pregnancies: (1) 26 (65%) resulted in term live delivery (TLD), 4 (10%) in PTLD between 34.0 weeks and 36.6 weeks, 5 (12.5%) in PTLD before 34th week, and 5 (12.5%) in fetal death (two associated with genetic anomalies); and (2) The aPL-related composite outcome occurred in 9 (23%). One of 26 (4%) pregnancies with TLD, 3/4 (75%) with PTLD between 34.0 weeks and 36.6 weeks, and 3/5 (60%) with PTLD before 34th week were complicated with PEC, SGA and/or PI. Fifty of 55 (91%) pregnancies were in lupus anticoagulant positive subjects, as well as all pregnancies with aPL-related composite outcome.Conclusion In our multicentre, international, aPL-positive cohort, of 55 first pregnancies observed prospectively, 15 (27%) were complicated by early pregnancy loss. Of the remaining 40 pregnancies, composite pregnancy morbidity was observed in 9 (23%) pregnancies
2023 ACR/EULAR antiphospholipid syndrome classification criteria
Objective: To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR.
Methods: This international multidisciplinary initiative included 4 phases: 1) Phase I, criteria generation by surveys and literature review; 2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; 3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and 4) Phase IV, validation using independent adjudicators' consensus as the gold standard.
Results: The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3âyears of identification of an aPL-associated clinical criterion, followed by additive weighted criteria (score range 1-7 points each) clustered into 6 clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and 2 laboratory domains (lupus anticoagulant functional coagulation assays, and solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti-ÎČ2-glycoprotein I antibodies). Patients accumulating at least 3 points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria versus the 2006 revised Sapporo classification criteria had a specificity of 99% versus 86%, and a sensitivity of 84% versus 99%.
Conclusion: These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk-stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research.</p
2023 ACR/EULAR antiphospholipid syndrome classification criteria
International audienceObjective. To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. Methods This international multidisciplinary initiative included four phases: (1) Phase I, criteria generation by surveys and literature review; (2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; (3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and (4) Phase IV, validation using independent adjudicatorsâ consensus as the gold standard. Results. The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL-associated clinical criterion, followed by additive weighted criteria (score range 1â7 points each) clustered into six clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and two laboratory domains (lupus anticoagulant functional coagulation assays, and solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM antiâÎČ 2 -glycoprotein I antibodies). Patients accumulating at least three points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria vs the 2006 revised Sapporo classification criteria had a specificity of 99% vs 86%, and a sensitivity of 84% vs 99%. Conclusion. These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk-stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research